Rehabtronics Receives $1.25 Million from Genome BC to Enable Free Quality Improvement Trials of Prelivia
The U.S. Food and Drug Administration has provided 510 (k) Clearance for Prelivia, a neurostimulation device that promotes healthy blood circulation and maintains healthy tissue in people who are bedridden or chair bound. Annually, more than 2.5 million people in the United States suffer from pressure injuries, also known as bed sores, and up to 60,000 people die.
The Centre for Aging + Brain Health Innovation (CABHI) awarded access to its Mentorship, Capital and Continuation (MC2) program to Rehabtronics in January. The program helps companies unlock funding to accelerate business growth by providing access to leading investors, buyers, industry leaders and advisory from Silicon Valley.